ライフサイエンスコーパス: highly aggressive

1 E) cancers range from relatively indolent to highly aggressive.

2 ural crest origin, and half of the cases are highly aggressive.

3 In support of this concept, metastasis of highly aggressive 4T1 breast cancer cells in mice can be

4 ival in animals injected subcutaneously with highly aggressive 4T1 cells revealed 5 of 5 deaths of PB

5 cing a chimaeric MLL oncogene give rise to a highly aggressive acute leukaemia associated with poor c

6 the brain for hundreds of genes between the highly aggressive Africanized honey bee compared with Eu

7 Highly aggressive Africanized honeybees (AHB) invaded Pu

8 ity of this new class of inhibitors to treat highly aggressive AML by targeting LICs.

9 ancer aggression and metastasis and HCC is a highly aggressive and angiogenic cancer.

10 and overexpress the cellular c-MYC gene are highly aggressive and carry a very poor prognosis.

11 he most lethal gynecologic malignancy; it is highly aggressive and causes almost 125,000 deaths yearl

12 Renal cancers are highly aggressive and clinically challenging, but a tran

13 oteolytic activity; metastatic melanoma is a highly aggressive and drug-resistant form of skin cancer

14 in humans and mice leads to an early onset, highly aggressive and fatal autoimmune disease affecting

15 Cutaneous malignant melanoma is a highly aggressive and frequently chemoresistant cancer,

16 a subset of small-cell lung cancer (SCLC), a highly aggressive and frequently lethal human tumour wit

17 Malignant pleural mesothelioma (MPM) is a highly aggressive and generally incurable cancer.

18 h it is known that these RESTless tumors are highly aggressive and include all tumor subtypes, the un

19 But in the setting of melanoma, a highly aggressive and invariably fatal malignancy in its

20 at Id-1 mRNA was constitutively expressed in highly aggressive and invasive human breast cancer cells

21 -rich networks in situ, has been observed in highly aggressive and malignant melanoma.

22 marate hydratase-deficient renal cancers are highly aggressive and metastasize even when small, leadi

23 oped advanced lung adenocarcinomas that were highly aggressive and metastasized to multiple intrathor

24 In contrast, nuclear extracts from highly aggressive and metastatic cell lines do not conta

25 Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic form of breast cancer t

26 Highly aggressive and metastatic melanoma cells are capa

27 n hepatocellular carcinoma (HCC) fostering a highly aggressive and metastatic phenotype.

28 pheral primitive neuroectodermal tumors, are highly aggressive and mostly affect children and adolesc

29 n lesions called leiomyomas (ULM), and rare, highly aggressive and pleomorphic tumors named leiomyosa

30 ) with respect to expression and function in highly aggressive and poorly aggressive human cutaneous

31 ised, these donor cells initiate a much more highly aggressive and rapidly fatal disease.

32 Pancreatic cancer is highly aggressive and refractory to existing therapies.

33 Pancreatic cancer is highly aggressive and refractory to most existing therap

34 overexpressing lung cancers, which are often highly aggressive and resistant to chemotherapy.

35 DLBCL exhibits highly aggressive and systemic progression into multiple

36 3-ITD-reconstituted animals, which died of a highly aggressive and transplantable AML within 3 to 5 m

37 ressors Tp53 or Ink4a/Arf in mice triggers a highly aggressive and transplantable precursor B-ALL.

38 euroendocrine malignant neoplasm that can be highly aggressive and ultimately lethal.

39 evidence that YAP is silenced in a subset of highly aggressive and undifferentiated human colorectal

40 Notch4ICD tumors were highly aggressive and well vascularized, indicating a ro

41 )Trp53(d/d) tumors in 12-month-old mice were highly aggressive, and metastasized to nearby and distan

42 The disease is highly aggressive, and survival is in the range of sever

43 The maize MuDR/Mu transposable elements are highly aggressive, and their activities are held in chec

44 The loss of T reg cells leads to fatal, highly aggressive, and widespread immune-mediated lesion

45 he Ggamma/T-15 transgenic line as a model of highly aggressive androgen-independent metastatic prosta

46 LSF in less aggressive HCC cells resulted in highly aggressive, angiogenic, and multiorgan metastatic

47 uences on mesocortical serotonin circuits in highly aggressive animals via feedback to autoreceptors

48 agenesis and cooperate with c-Myc to produce highly aggressive B cell lymphomas.

49 Mantle cell lymphoma (MCL) is a highly aggressive B-cell lymphoma resistant to conventio

50 Primary effusion lymphoma (PEL) is a highly aggressive B-cell malignancy that is closely asso

51 Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma (B-NHL), w

52 f FOXC2 is significantly correlated with the highly aggressive basal-like subtype of human breast can

53 cribed as particularly effective against the highly-aggressive basal/triple-negative subtype of breas

54 st cancer cells and shore hypomethylation in highly aggressive, basal-like cells.

55 were consistently overexpressed in the more highly aggressive BC cells.

56 fourth of ES cases and define a subset with highly aggressive behavior and poor chemoresponse.

57 ignant melanoma (CMM), already known for its highly aggressive behavior and resistance to conventiona

58 n acts as an oncogene and contributes to the highly aggressive behavior of this tumor.

59 As these tumors exhibited highly aggressive behavior, the possibility of exploitin

60 es of cancer cell lines from two E2F1-driven highly aggressive bladder and breast tumors, and use net

61 n kinase (MAPK) pathway that is deficient in highly aggressive BLBCs treated with chemotherapy, leadi

62 ell metastatic propensities, being lowest in highly aggressive BMBC cell variants compared with eithe

63 Glioblastoma multiforme (GBM) is a highly aggressive brain cancer that is characterized by

64 Glioblastoma is a highly aggressive brain tumor.

65 Malignant gliomas are highly aggressive brain tumors that display many of thes

66 y potentially improve the treatment of these highly aggressive brain tumors.

67 Glioblastoma are highly aggressive brain tumours that are associated with

68 We further show that, in the highly aggressive breast cancer cell line MDAMB231, wher

69 melanocyte-specific proteins as did another highly aggressive breast cancer cell line.

70 methylation in several cancers, whereas some highly aggressive breast cancer cells exhibit genomic lo

71 tatic breast cancer cell lines as well as in highly aggressive breast cancer specimens.

72 Claudin-low tumors are a highly aggressive breast cancer subtype with no targeted

73 minogen activation receptor (uPAR, PLAUR) in highly aggressive breast cancer subtypes and cell lines.

74 11 signatures sharing a phenotype related to highly aggressive breast cancer.

75 ith Her2/neu proto-oncogene amplification in highly aggressive breast cancers and induced by Her2/neu

76 gn lesions and could also define a subset of highly aggressive breast cancers.

77 nterfering RNA directed to ERRalpha into the highly aggressive breast carcinoma MDA-MB-231 cell line

78 Highly aggressive Burkitt lymphoma (BL) with rapidly pro

79 NUT midline carcinoma (NMC) is a rare but highly aggressive cancer typically caused by the translo

80 Hepatocellular carcinoma (HCC) is a highly aggressive cancer with no currently available eff

81 Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few tre

82 r clear cell renal cell carcinoma (ccRCC), a highly aggressive cancer.

83 ial molecular target for the therapy of this highly aggressive cancer.

84 issue-level program supporting the growth of highly aggressive cancers and early-stage metastases.

85 hotothermal transducers for the treatment of highly aggressive cancers and large tumors where the pen

86 Mutation of p53 is indicative of highly aggressive cancers and poor prognosis.

87 it exhibits moderate to poor effects against highly aggressive cancers including triple-negative and

88 sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early childhood characteriz

89 ver 50% of all cancers and are indicative of highly aggressive cancers that are hard to treat.

90 s therapeutic lead compounds for a number of highly aggressive cancers.

91 ally advantageous for treating many types of highly aggressive cancers.

92 10 of 45 cases of poorly differentiated and highly aggressive carcinoma with metaplastic morphology.

93 aggressiveness, possibly suggesting that in highly aggressive cell lines, key signaling enzymes are

94 g and mRNA was dramatically increased in the highly aggressive cell lines, such as MDA-231, relative

95 The highly aggressive character of melanoma makes it an exce

96 n in adult T-cell leukemia/lymphoma (ATL), a highly aggressive chemotherapy-resistant malignancy.

97 SMARCB1 gene in malignant rhabdoid tumors, a highly aggressive childhood cancer.

98 BCR-ABL1-Abl1(-/-) cells generated highly aggressive chronic myeloid leukemia (CML)-blast p

99 tics, and the mechanisms responsible for the highly aggressive clinical picture of hepatocellular car

100 Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous neuroendocrine tumor.

101 eficiency viruses (SIV), displayed mildly or highly aggressive cytopathic phenotypes depending on the

102 Ovarian cancer is a highly aggressive disease and novel treatments are requi

103 2-positive (HER2(+)) breast cancer (BC) is a highly aggressive disease commonly treated with chemothe

104 Melanoma is a highly aggressive disease that is difficult to treat owi

105 Esophageal adenocarcinoma (EAC) is a highly aggressive disease with poor long-term survival.

106 pite major advances in the treatment of this highly aggressive disease with potent inhibitors of the

107 d with triple-negative tumors that represent highly aggressive disease.

108 loping new treatments for patients with this highly aggressive disease.

109 gains and structural rearrangements to form highly aggressive disease.

110 apies to improve the dismal outcomes in this highly aggressive disease.

111 trast, BJ3Z cells do not alter the growth of highly aggressive ER-negative MDA-MB-231 human breast ca

112 Furthermore, these formerly highly aggressive flies lose all competitive advantage o

113 After a defeat, however, these highly aggressive flies lose their second fights against

114 pression of hIL-1 beta resulted in a severe, highly aggressive form of arthritis analogous to chronic

115 Glioblastoma is a highly aggressive form of brain cancer characterized by

116 Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that exhibits ex

117 e-negative breast cancer (TNBC) represents a highly aggressive form of breast cancer with limited tre

118 ancer vaccines or immunotherapy against this highly aggressive form of breast cancer.

119 tions identify a phenotypically distinct and highly aggressive form of MCL with poor or no response t

120 s a Gram-negative bacterium that can cause a highly aggressive form of neonatal meningitis, which oft

121 vary, hypercalcemic type (SCCOHT) is a rare, highly aggressive form of ovarian cancer primarily diagn

122 MCPyV is associated with a highly aggressive form of skin cancer in humans.

123 Melanoma is the most serious, highly aggressive form of skin cancer with recent dramat

124 Merkel cell carcinoma is a highly aggressive form of skin cancer.

125 Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of the disease for which new ther

126 ntact genes than those pathways described in highly aggressive forms of myc-related murine preB cell

127 expression of PKCalpha mRNA was detected in highly aggressive glioblastoma multiforme as compared wi

128 ssion of EGFRvIII variants as a signature of highly aggressive gliomas and to identify patients that

129 whether it functions as an oncogene in this highly aggressive group of bone and soft tissue tumors.

130 V insertion in the human genome supports the highly aggressive growth of human choriocarcinoma and po

131 onomous feature that exerts its detrimental, highly aggressive growth potential upon escape from cell

132 ificantly abrogated growth and metastasis of highly aggressive HCC cells in nude mice.

133 HCC with partial penetrance and exhibit more highly aggressive HCC induced by chemical carcinogenesis

134 asis, whereas Alb/AEG-1/c-Myc mice developed highly aggressive HCC with frank metastasis to the lungs

135 Triple-negative breast cancer (TNBC) is a highly aggressive, heterogeneous disease with poor progn

136 Glioblastoma multiforme is the most common highly aggressive human brain cancer, and receptor tyros

137 ved in promoting the growth of a subclass of highly aggressive human GBMs that lack EGF receptor ampl

138 PFE (10-100 microg/ml; 48 h) treatment of highly aggressive human prostate cancer PC3 cells result

139 uced single copies of hchr7 or hchr12 into a highly aggressive human prostate carcinoma cell line (PC

140 ited in Trp53(-/-)Ssbp2(-/-) mice to develop highly aggressive, immature thymic lymphomas.

141 ter gene inserted into the viral vpr gene is highly aggressive in depleting human myeloid and erythro

142 They can be highly aggressive in subsequent interactions, supporting

143 transmitted through organ transplants and is highly aggressive in transplant recipients.

144 t(15;19)(q13, p13.1) is characterized by its highly aggressive, invariably lethal clinical course.

145 We found that grade 3 tumours are highly aggressive irrespective of stage.

146 ctly injecting the preformed conjugates into highly aggressive L5178Y-R lymphomas grown intradermally

147 Triple-negative breast cancers (TNBC) are highly aggressive, lack FDA-approved targeted therapies,

148 oids are not early progenitor lesions of the highly aggressive lung neuroendocrine tumours but arise

149 xposure to an environmental PAH can induce a highly aggressive lymphoma in mice and raises the possib

150 10 anaplastic large-cell lymphomas), and 15 highly aggressive lymphomas (7 lymphoblastic lymphomas a

151 Most cases of aggressive and highly aggressive lymphomas showed strong expression of

152 ular features with Burkitt lymphoma (BL) are highly aggressive lymphomas with poor clinical outcome.

153 The invasive ability of the highly aggressive Mahlavu cell was attenuated by pre-miR

154 Uterine carcinosarcomas (UCSs) are highly aggressive malignancies associated with poor prog

155 primitive neuroectodermal tumors (PNET), are highly aggressive malignancies predominantly affecting c

156 ancreatic and bile duct carcinomas represent highly aggressive malignancies that evolve from secretin

157 Early detection of the highly aggressive malignancy cholangiocarcinoma (CCA) re

158 Metastatic melanoma is a highly aggressive malignancy that has traditionally been

159 Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal survival rate

160 or and HER2 (also called ERBB2 or NEU)--is a highly aggressive malignancy with limited treatment opti

161 Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor survival rates, w

162 ntracranial glial neoplasms ranging from the highly aggressive malignant glioblastoma multiforme (GBM

163 arsenic, as confirmed by the development of highly aggressive, malignant tumors after inoculation of

164 Pancreatic cancer is highly aggressive, malignant, and notoriously difficult

165 agonistic differences, with bHRs acting in a highly aggressive manner when facing homecage intrusion.

166 dactyl clubs of the stomatopods, a group of highly aggressive marine crustaceans.

167 ms identifies Burkitt lymphoma/leukemia as a highly aggressive mature B-cell neoplasm consisting of e

168 gen peroxide (H(2)O(2)), particularly in the highly aggressive MDA-MB-231 breast cancer cells.

169 ly affected by ectopic expression of REST in highly aggressive MDA-MB-231 cells.

170 -interference-mediated knockdown of SATB1 in highly aggressive (MDA-MB-231) cancer cells altered the

171 We have discovered that in WM1158, a highly aggressive melanoma cell line, down-regulation of

172 l (VE)-cadherin was exclusively expressed by highly aggressive melanoma cells and was undetectable in

173 rs that appear to be aberrantly expressed in highly aggressive melanoma cells, causing melanoma cell

174 a pluripotent embryonic-like genotype in the highly aggressive melanoma cells.

175 The procoagulant function of TF on highly aggressive melanoma is shown to be regulated by T

176 Furthermore, growth of highly aggressive melanoma isograft tumors was suppresse

177 mimicry (VM) describes the unique ability of highly aggressive melanoma tumor cells to express endoth

178 hat are derived from tumors characterized by highly aggressive metastatic behavior.

179 tubular networks in vitro, a feature of some highly aggressive metastatic melanomas.

180 Highly aggressive, metastatic melanoma is notoriously re

181 ve breast cancer, or basal breast cancer, is highly aggressive, metastatic, and difficult to treat.

182 nificant extension in lifespan, even in this highly aggressive model of disease.

183 in relatively unchanged for less common, but highly aggressive, mold infections such as mucormycosis.

184 EGFR overexpression is a characteristic of highly aggressive molecular subtypes of breast cancer wi

185 ATSM in a mouse breast tumor model using the highly aggressive mouse mammary carcinoma cell line EMT-

186 l breach in immunological tolerance, causing highly aggressive multi-organ autoimmune pathology.

187 The highly aggressive muscle cancer alveolar rhabdomyosarcom

188 nd demonstrate that mutant females develop a highly aggressive myeloproliferative neoplasm and myelod

189 deadliest form of skin cancer because of its highly aggressive nature and the lack of effective treat

190 Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive neoplasm characterized by a marked fib

191 ign noninvasive imaging techniques to detect highly aggressive neoplasms and their metastases.

192 Melanomas are highly aggressive neoplasms resistant to most convention

193 Malignant gliomas are highly aggressive neoplasms that are very resistant to c

194 Malignant melanoma is a highly aggressive neoplastic disease whose incidence is

195 ng RNA reduced the tumorigenic properties of highly aggressive neuroblastoma cells.

196 Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer with profou

197 sociated with Merkel cell carcinoma (MCC), a highly aggressive neuroendocrine skin cancer.

198 ntribute to the oncogenic progression in the highly aggressive NMC.

199 expression promoter was transfected into the highly aggressive, nonimmunogenic MCA 101 murine sarcoma

200 p significantly repressed tumour growth in a highly aggressive NSCLC circulating tumour cell (CTC) pa

201 translocation t(15;19) that accounts for the highly aggressive NUT midline carcinoma (NMC).

202 Conjunctival melanoma (CM) is a highly aggressive ocular cancer for which treatment opti

203 mplified gene in human cancer, including the highly aggressive ovarian serous carcinoma.

204 A highly aggressive ovarian xenograft model was establishe

205 provide solvent-free product, and the use of highly aggressive oxidants, such as iodine monochloride.

206 er than risk their patients' deaths by using highly aggressive pain treatments.

207 ncreased in various human cancers, including highly aggressive pancreatic cancers, but the mechanisms

208 s, synovial hypertrophy and hyperplasia, and highly aggressive pannus formation with erosion of the a

209 33 is seen more frequently in cancers of the highly aggressive papillary serous type than in cancers

210 Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor characterize

211 utic target and treatment approach for these highly aggressive pediatric cancers.

212 (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.

213 Rhabdoid tumors (RTs) are rare, highly aggressive pediatric malignancies with poor progn

214 outcomes for this biologically distinct and highly aggressive pediatric malignancy.

215 bserved in malignant rhabdoid tumor (MRT), a highly aggressive pediatric neoplasm.

216 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma.

217 cation as a central genetic determinant of a highly aggressive phenotype that directs the worst clini

218 erved that these cells were converted into a highly aggressive phenotype, as primary tumors that form

219 tive p53-/- cells produced a transplantable, highly aggressive, poorly differentiated acute myelogeno

220 f the central nervous system (CNS-PNETs) are highly aggressive, poorly differentiated embryonal tumor

221 e channels in histological preparations from highly aggressive primary uveal melanomas, in the vertic

222 ells as a test model system because of their highly aggressive proliferative nature.

223 We found that ZEB1 is expressed in highly aggressive prostate cancer cells and that its exp

224 s suggested reduced functional activities in highly aggressive prostate cancer compared with less agg

225 of early malignant changes and subsequently highly aggressive prostate tumors at a younger age, comp

226 ar double-step processes, each of which uses highly aggressive reagents, and each generates substanti

227 ith that of podoplanin during progression to highly aggressive SCCs in a mouse skin model of carcinog

228 Merkel cell carcinoma (MCC) is a rare and highly aggressive skin cancer associated with the Merkel

229 sheath tumors (MPNSTs) represent a group of highly aggressive soft-tissue sarcomas that may occur sp

230 noculated directly into primary 4T1 tumor, a highly aggressive, spontaneously metastasizing mammary c

231 Triple-negative breast cancer (TNBC) is a highly aggressive subcategory of breast cancer and curre

232 Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited tr

233 eral nerve sheath tumors (MPNST), a class of highly aggressive, therapeutically resistant, and common

234 MPNSTs are highly aggressive, therapeutically resistant, and typica

235 analysis comparing low aggressive TM40D and highly aggressive TM40D-MB mouse mammary carcinoma cells

236 herapeutic strategy to treat drug-resistant, highly aggressive TNBC tumors.

237 as a novel BRD4-NUT target that supports the highly aggressive transforming activity of t(15;19) carc

238 Pancreatic cancer is a highly aggressive, treatment refractory cancer and is th

239 time of mice bearing large (>1000mm(3)) and highly aggressive triple negative breast tumors is doubl

240 Efforts to improve the clinical outcome of highly aggressive triple-negative breast cancer (TNBC) h

241 added diagnostic benefit in identifying the highly aggressive triple-negative cancer phenotype with

242 e Notch3 receptor has been correlated to the highly aggressive "triple negative" human breast cancer.

243 ogy domains-1) was strongly expressed in the highly aggressive tumor cells with a low level of expres

244 of cancer, including medulloblastoma (MB), a highly aggressive tumor of the cerebellum.

245 Cutaneous melanoma is a highly aggressive tumor that is relatively resistant to

246 Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with poor prognosis.

247 nal in protecting mice from challenge with a highly aggressive tumor, (b) that this vaccine can direc

248 Pancreatic cancer is a highly aggressive tumor, mostly resistant to the standar

249 d led to the eradication of well-established highly aggressive tumors and the development of long-ter

250 2.2, 28.6) but was elevated for moderate and highly aggressive tumors as well (odds ratios = 6.6 and

251 d many breast cancer cell lines derived from highly aggressive tumors contain high levels of activate

252 MidT2-1 cells gave rise to highly aggressive tumors in syngeneic FVB mice in both t

253 e cell lines with altered Ron protein formed highly aggressive tumors in the lungs.

254 hed tumor stem cell population, resulting in highly aggressive tumors in vivo.

255 iffuse intrinsic pontine gliomas (DIPGs) are highly aggressive tumors of childhood that are almost un

256 Malignant gliomas are highly aggressive tumors of the central nervous system t

257 Malignant mesotheliomas are highly aggressive tumors usually caused by exposure to a

258 Pancreatic cancer, a highly aggressive tumour type with uniformly poor progno

259 ransplantation of transformed iNPCs leads to highly aggressive tumours containing undifferentiated st

260 general associated with a worse outcome, but highly aggressive tumours with 11q13-14 amplification ha

261 K fusion occurs in a subset of patients with highly aggressive types of thyroid cancer and provide in

262 ast, miR-375 is strikingly down-regulated in highly aggressive, undifferentiated MCC cell lines.

263 Hepatocellular carcinoma (HCC) is a highly aggressive vascular cancer characterized by diver

264 onverted nontumorigenic human HCC cells into highly aggressive vascular tumors, and inhibition of AEG

265 y analysis from our laboratory comparing the highly aggressive versus the poorly aggressive melanoma

266 Additionally, TTP(min) can help identify highly aggressive WHO III astrocytoma tumors and may hel

267 These tumors are highly aggressive with a median survival of less than 2

268 Basal-like breast cancers (BLBC) are highly aggressive, yet selective therapies targeting the